Xencor, Inc.
XNCR
|
$18.385
-2.98%
-3.07%
830K
|
Health Technology
(0.0% 1d) (-19.4% 1m) (-36.2% 1y) (0.0% 2d) (-3.6% 3d) (-8.6% 7d) (82.78% volume)
Earnings Calendar: 2024-02-22
Market Cap: $ 1,123,696,201
http://www.xencor.com
Sec Filling | Patents | 166 employees
(United States) Xencor, Inc. engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.
cancer antibody autoimmunity monoclonal antibodies
add to watch list Paper trade email alert is off
Press-releases
Xencor Appoints Bart Cornelissen as Chief Financial Officer
Published: 2024-04-09 (Crawled : 13:00) - biospace.com/
XNCR | $18.385 -2.98% -3.07% 830K
|
Health Technology
|
| O: -0.28%
H: 3.95%
C: 1.32%
financial
MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Published: 2024-03-13 (Crawled : 23:00) - biospace.com/
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.07%
H: 0.09%
C: -0.7%
XNCR | $18.385 -2.98% -3.07% 830K
|
Health Technology
|
| O: -0.66%
H: 4.19%
C: 3.13%
MOR | News | $17.96 -0.5% -0.5% 180K
|
Health Technology
|
| O: 0.22%
H: 0.22%
C: -0.93%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.03%
H: 1.47%
C: -0.72%
year update financial results
Knight Therapeutics Announces Launch of Minjuvi® in Brazil
Published: 2024-02-29 (Crawled : 12:30) - globenewswire.com
XNCR | $18.385 -2.98% -3.07% 830K
|
Health Technology
|
| O: 2.68%
H: 2.22%
C: -1.92%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.38%
H: 0.0%
C: -3.07%
minjuvi brazil therapeutics
Xencor Reports Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-02-27 (Crawled : 00:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -1.07%
H: 0.0%
C: 0.0%
XNCR | $18.385 -2.98% -3.07% 830K
|
Health Technology
|
| O: 1.2%
H: 2.52%
C: 1.3%
year financial results
BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
Published: 2024-02-26 (Crawled : 12:00) - biospace.com/
XNCR | $18.385 -2.98% -3.07% 830K
|
Health Technology
|
| O: -0.29%
H: 7.38%
C: 6.02%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 2.6%
H: 1.87%
C: 0.7%
business year financial results
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-02-22 (Crawled : 00:00) - biospace.com/
XNCR | $18.385 -2.98% -3.07% 830K
|
Health Technology
|
| O: -0.87%
H: 2.89%
C: 2.14%
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: -0.69%
H: 2.99%
C: 2.59%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: -0.17%
H: 6.18%
C: 5.4%
year update financial results
Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update
Published: 2024-02-20 (Crawled : 00:00) - biospace.com/
XNCR | $18.385 -2.98% -3.07% 830K
|
Health Technology
|
| O: -1.08%
H: 4.04%
C: -1.63%
year review update financial results
Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities
Published: 2024-02-13 (Crawled : 19:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.14%
H: 0.35%
C: 0.07%
XNCR | $18.385 -2.98% -3.07% 830K
|
Health Technology
|
| O: -3.56%
H: 2.91%
C: -3.34%
MOR | News | $17.96 -0.5% -0.5% 180K
|
Health Technology
|
| O: -0.4%
H: 0.23%
C: -0.46%
MGNX | $15.62 -2.8% -2.88% 1M
|
Health Technology
|
| O: -5.25%
H: 2.94%
C: 2.18%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 3.8%
H: 1.1%
C: -1.17%
financial
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS
Published: 2024-02-06 (Crawled : 21:00) - prnewswire.com
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.14%
H: 0.35%
C: -1.12%
XNCR | $18.385 -2.98% -3.07% 830K
|
Health Technology
|
| O: -0.05%
H: 0.0%
C: -2.09%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.33%
H: 0.0%
C: 0.0%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -3.53%
H: 1.53%
C: -0.27%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.18%
H: 0.0%
C: -6.22%
year financial results
Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)
Published: 2024-02-05 (Crawled : 23:00) - biospace.com/
XNCR | $18.385 -2.98% -3.07% 830K
|
Health Technology
|
| O: -1.55%
H: 2.76%
C: 1.84%
MOR | News | $17.96 -0.5% -0.5% 180K
|
Health Technology
|
| O: 0.99%
H: 59.84%
C: 54.47%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.6%
H: 0.81%
C: 0.1%
monjuvi global commercialization
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
GBR | $1.42 31.48% 11.27% 990K
|
Energy Minerals
KUKE | $2.88 2.49% 7.64% 360K
|
SYY | $76.73 1.44% 5.49% 2.5M
|
Distribution Services
TWI | $11.53 0.96% 4.94% 330K
|
Producer Manufacturing
BTCM | $1.99 -6.13% 4.52% 75K
|
Arts, Entertainment, and Recrea...
MPLN | $0.6502 -11.74% 4.51% 2.2M
|
Finance
CXM 4 | $11.34 -0.44% 4.27% 1.7M
|
Information
UHS | $157.47 2.49% 4.13% 900K
|
Health Services
PVL 4 | $1.47 -0.68% 4.08% 77K
|
Energy Minerals
Last 48 Hours Insiders Buying
RXO P 200000 | $19.37 2.32% 0.0% 1M
|
n/a
|
23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M
|
Finance
|
22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K
|
Health Technology
|
22:30
BCDA P 2750 | $0.377 -1.4% 97K
|
Health Technology
|
22:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10